Literature DB >> 18483255

Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint.

Haomin Huang1, Lynda Fletcher, Neil Beeharry, Rene Daniel, Gary Kao, Tim J Yen, Ruth J Muschel.   

Abstract

X-irradiation-induced DNA damage perturbs the G(1), S, and G(2) phases of the cell cycle. The behavior of cells after they have experienced a DNA damage checkpoint delay is poorly characterized. We therefore examined the fates of irradiated tumor cells that have overcome a prolonged G(2) checkpoint delay. Most irradiated cells progressed through mitosis without significant delay, but failed to complete cytokinesis as they remained tethered to each other at the midbody. We observed that the movement of centrioles at the time of cytokinesis was impaired in the irradiated, bridged cells. We attribute the perturbation of centriole dynamics to the presence of chromatin bridges that spanned the daughter cells. The bridged cells exhibited different fates that included death, fusion that formed multinucleated cells, or another round of mitosis with no noticeable cell cycle delays. The presence of gammaH2AX foci in the bridge as well as in the separated nuclei indicated that cells were proliferating despite the presence of DNA damage. It seems that DNA damage checkpoints were not reactivated in cells that overrode a prolonged G(2) delay. Cells deficient in ATM, H2AX, XRCC3, or ligase 4 exhibited a higher frequency of radiation-induced bridges than controls, suggesting that the DNA bridges resulted from inadequate DNA repair. These data show a previously unappreciated cytologic hallmark of DNA damage in dividing cells. Chromatin bridges that interfere with cytokinesis are likely to contribute to the replication failure and clonogenic death of cells exposed to irradiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483255     DOI: 10.1158/0008-5472.CAN-08-0479

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells.

Authors:  Patrizia Vinciguerra; Susana A Godinho; Kalindi Parmar; David Pellman; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  The influence of ADAR1's regulation on lymphocyte cell function during rejection.

Authors:  Lei Cai; Yan Li; Feng Liu; Wei Zhang; Binliang Huo; Wei Zheng; Rui Ding; Jiyuan Guo; Qingchuan Zhao; Kefeng Dou
Journal:  Mol Biol Rep       Date:  2009-09-15       Impact factor: 2.316

3.  The NF90/NF45 complex participates in DNA break repair via nonhomologous end joining.

Authors:  Raghavendra A Shamanna; Mainul Hoque; Anita Lewis-Antes; Edouard I Azzam; David Lagunoff; Tsafi Pe'ery; Michael B Mathews
Journal:  Mol Cell Biol       Date:  2011-10-03       Impact factor: 4.272

4.  MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Authors:  Kathleen A Bridges; Hiroshi Hirai; Carolyn A Buser; Colin Brooks; Huifeng Liu; Thomas A Buchholz; Jessica M Molkentine; Kathryn A Mason; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2011-07-28       Impact factor: 12.531

5.  Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion.

Authors:  Manoranjan Santra; Sutapa Santra; Cindi Roberts; Rui Lan Zhang; Michael Chopp
Journal:  J Neurochem       Date:  2009-01       Impact factor: 5.372

Review 6.  Mitogen-activated protein kinases and their role in radiation response.

Authors:  Anupama Munshi; Rajagopal Ramesh
Journal:  Genes Cancer       Date:  2013-09

7.  Single doublecortin gene therapy significantly reduces glioma tumor volume.

Authors:  Manoranjan Santra; Xuguang Zheng; Cindi Roberts; Sutapa Santra; Mei Lu; Swayamprava Panda; Feng Jiang; Michael Chopp
Journal:  J Neurosci Res       Date:  2010-02-01       Impact factor: 4.164

8.  In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.

Authors:  Eun Joo Chung; Aaron P Brown; Hiroaki Asano; Mariana Mandler; William E Burgan; Donna Carter; Kevin Camphausen; Deborah Citrin
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

9.  A role for XRCC2 gene polymorphisms in breast cancer risk and survival.

Authors:  Wei-Yu Lin; Nicola J Camp; Lisa A Cannon-Albright; Kristina Allen-Brady; Sabapathy Balasubramanian; Malcolm W R Reed; John L Hopper; Carmel Apicella; Graham G Giles; Melissa C Southey; Roger L Milne; Jose I Arias-Pérez; Primitiva Menéndez-Rodríguez; Javier Benítez; Magdalena Grundmann; Natalia Dubrowinskaja; Tjoung-Won Park-Simon; Thilo Dörk; Montserrat Garcia-Closas; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Douglas F Easton; Alison M Dunning; Preetha Rajaraman; Alice J Sigurdson; Michele M Doody; Martha S Linet; Paul D Pharoah; Marjanka K Schmidt; Angela Cox
Journal:  J Med Genet       Date:  2011-05-31       Impact factor: 6.318

10.  Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.

Authors:  Eduardo C Filippi-Chiela; Marcos Paulo Thomé; Mardja Manssur Bueno e Silva; Alessandra Luíza Pelegrini; Pitia Flores Ledur; Bernardo Garicochea; Lauren L Zamin; Guido Lenz
Journal:  BMC Cancer       Date:  2013-03-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.